3 hours Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Overweight Rating from Piper Sandler MarketBeat
Piper Sandler restated an “overweight” rating and issued a $62.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday.
Nasdaq 100 · Pharmaceuticals · Science